← Dashboard
Oct 25, 2026 04:40 PM ET
Signal
FDA/Bio
AstraZeneca stomach cancer drug doubles survival in late-stage trial
AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial.
What changed
AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial.
Why it matters
AstraZeneca’s stomach cancer drug doubled survival in a late-stage trial. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
In reversal, American Cancer Society urges routine prostate cancer screening →
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →